Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This study suggests that Aldactone may be more effective than Diane in reducing hair growth, despite having minimal impact on hormone levels.

This study identified serum androsterone as a robust biomarker for monitoring response to AKR1C3 inhibitor treatment in women and found that a 4-week administration of aldo-keto reductase 1C3 inhibitors did not impact ovarian function.

AKR1B10 enzyme may cause keloid scars and could be a treatment target.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.